At the end of this session, participants will be able to:
- Describe the challenges of combining TKIs with immunotherapy for gynecologic cancers
- Identify how to manage toxicity related to IO and TKI combinations
- Determine the optimal approach to monitoring patients on this therapy
The event time is in EST.